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Abstract
Overexpression of the de-ubiquitinating enzyme UCH-L1 leads to inclusion formation in response to proteasome
impairment. These inclusions contain components of the ubiquitin-proteasome system and a-synuclein confirming that the
ubiquitin-proteasome system plays an important role in protein aggregation. The processes involved are very complex and
so we have chosen to take a systems biology approach to examine the system whereby we combine mathematical
modelling with experiments in an iterative process. The experiments show that cells are very heterogeneous with respect to
inclusion formation and so we use stochastic simulation. The model shows that the variability is partly due to stochastic
effects but also depends on protein expression levels of UCH-L1 within cells. The model also indicates that the aggregation
process can start even before any proteasome inhibition is present, but that proteasome inhibition greatly accelerates
aggregation progression. This leads to less efficient protein degradation and hence more aggregation suggesting that there
is a vicious cycle. However, proteasome inhibition may not necessarily be the initiating event. Our combined modelling and
experimental approach show that stochastic effects play an important role in the aggregation process and could explain the
variability in the age of disease onset. Furthermore, our model provides a valuable tool, as it can be easily modified and
extended to incorporate new experimental data, test hypotheses and make testable predictions.
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Introduction
UCH-L1 (P09936) is a de-ubiquitinating enzyme (DUB) which
binds to small polyubiquitinated proteins and cleaves ubiquitin
molecules (P62988). However, as yet its substrates are unknown. It
also binds to ubiquitin and stabilises ubiquitin pools [1]. When
UCH-L1 is overexpressed it may form dimers which have
ubiquitin ligase (E3) activity [2]. E3 ligases bind to specific
substrates and accept ubiquitin molecules from ubiquitin-conju-
gating (E2) enzymes which are then attached to the substrate via
an isopeptide bond. UCH-L1 is normally abundant in brain tissue
where it is localised to neurons (1-2% of soluble neuronal cell
protein) [3]. It is also highly expressed in testes but UCH-L1 levels
are low in all other tissues due to silencing by methylation [4].
UCH-L1 expression levels have been associated with several
cancer types. It is up-regulated in some cancers; for example it is
over-expressed in lung cancer [5]. However there is increased
silencing of the UCH-L1 gene in human colorectal and ovarian
cancers [6]. UCH-L1 is also found in Lewy bodies of Parkinson’s
disease (PD) patients and tangles in Alzheimer’s disease (AD)
patients [7]. It is oxidatively damaged in these diseases and loses
about 40–80% of its activity [8]. There is also reduced protein
expression of UCH-L1 in PD and AD [9]. This reduction could be
due to an increase in damaged UCH-L1 which is then sequestered
into inclusions. For example, the level of soluble UCH-L1 protein
is inversely proportional to the number of tangles in AD brains [9].
The UCH-L1 gene is also known as PARK5 and mutations in this
gene are linked to PD [10,11]. The I93M mutation has severely
diminished hydrolase activity and lower E3 activity compared to
WT [2] and it has been suggested that it is linked to disease,
although there is controversy regarding this relationship [12].
Recently it was shown that the I93M mutant resembles
oxidatively-damaged UCH-L1 in that it has increased insolubility
and increased interaction with the Lamp2a (P13473) receptor
compared with wild-type UCH-L1 [8,13,14]. On the other hand,
the S18Y polymorphism may be associated with decreased
susceptibility of sporadic PD in a dose-dependent manner,
although the evidence for this may be weak [15] or moderate at
most [16]. The S18Y mutant has greater hydrolase activity but
much lower E3 activity than WT [2,8,17]. One of its substrates is
a-synuclein but in this case UCH-L1 forms K63-linked ubiquitin
chains which are not recognised as a degradation signal by the
proteasome. Moreover, the E3 activity of UCH-L1 has only been
seen in vitro and so far this data has not been replicated.
UCH-L1 is susceptible to oxidative damage and when this
occurs it has aberrant functions similar to mutated UCH-L1, as
already mentioned. Abnormal UCH-L1 interacts with Lamp2a,
Hsc70 (P11142) and Hsp90 (P07900), and may inhibit chaperone
mediated autophagy (CMA)-dependent degradation causing CMA
substrates, e.g. a-synuclein (P37840) and GAPDH (P04406), to
accumulate [13,14]. UCH-L1 is a long-lived protein with a half-
life greater than 48 h and is mainly turned over by macro-
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inhibited suggesting additional turnover by the proteasome [18].
Cellular proteins are susceptible to damage and prone to
misfolding. Misfolded proteins may be refolded via the chaperone
pathway, or targeted for degradation via the ubiquitin-proteasome
pathway. Misfolded proteins may also aggregate and this may
happen after the misfolded protein has been targeted for
degradation so that ubiquitin and DUBs are sequestered into the
aggregate along with the misfolded protein. If the misfolded
protein is a UCH-L1 substrate, then UCH-L1 will also end up in
aggregates.
a-synuclein is abundantly expressed in human brain (low levels
are also found in all other tissues except liver). It is natively
unfolded but does not self-aggregate unless it is present at very
high levels [19]. However, mutations and oxidative damage can
lead to an increase in its propensity to aggregate [20]. It is a fairly
stable protein with a half-life of about 16 hours [21], although it
has also been shown that its half-life is greater than 19 hours [22].
It has been shown in vitro that it can be degraded by the 20S
proteasome in a ubiquitin-independent manner [22] and there is
also in vivo evidence that it is degraded by CMA [23]. If a-
synuclein is oxidatively damaged then it is degraded by the
ubiquitin-proteasome pathway. For example, the early onset
Parkinson’s disease associated protein, Parkin (O60260), which
has E3 ligase activity, is involved in the polyubiquitination of O-
glycosylated a-synuclein [24,25]. Data suggest a-synuclein is
phosphorylated prior to ubiquitination [26]. Parkin also ubiqui-
tinates the a-synuclein-interacting protein, synphilin-1, with both
Lys48 and Lys63-linked polyubiquitin chains [27]. However,
Lys48 linkages which lead to degradation are only formed when
the parkin/synphilin-1 ratio is unusually high.
There have been many in vitro studies of protein aggregation
kinetics and many mechanisms and mathematical models have
been proposed (see Morris et al 2009 for a recent review) [28].
Although many different schemes for protein aggregation have
been proposed, there is a general consensus that there are three
main steps. Firstly, the protein monomer has to undergo some
modification before it has a propensity to aggregate. Secondly,
there is a nucleation step, where monomers interact to form small
aggregates. This stage is very slow and also reversible. However,
the small aggregates formed at this stage may be toxic to cells as
they may interact with cellular components. In particular, they can
inhibit the proteasome which is unable to degrade aggregated
protein. The third stage begins once the aggregate has reached a
certain size, often termed the ‘‘nucleus’’ or the ‘‘seed’’ and is called
the elongation stage. At this point, the aggregates irreversibly and
rapidly grow in size forming protofilaments and fibrils that are
typical in neurodegeneration. Different mechanisms have been
proposed for the elongation stage such as the addition of
monomers or the assembly of oligomers. Plots of aggregation
kinetics typically give rise to a sigmoidal curve which has a lag
phase before any aggregation takes place, followed by a sharp
increase after nucleation and finally a plateau due to all the protein
in the in vitro studies being incorporated into the aggregates (see
Figure 1). Many examples of aggregation kinetics based on
experimental data and a range of deterministic models are shown
in a recent review [28].
Based on our previous work [18], we have set up an
experimental system to study the kinetics of inclusion formation
where UCH-L1 is overexpressed and proteasome activity is
inhibited. In order to gain more insights into the processes
involved, we have also constructed a stochastic mechanistic model
using the Systems Biology Markup Language (SBML) [29]. We
used the model to examine the effects of both UCH-L1 expression
and proteasome activity on the aggregation process. Since there is
controversy over the effects of mutant forms of UCH-L1 we also
used the model to investigate the nature of the mutations and then
did further experiments to test the model predictions.
Results
Normal conditions
We adjusted the model parameters so that protein levels remain
constant over time with just small fluctuations due to the stochastic
component of protein synthesis and degradation (Figure 2). The
model predicts that no damage occurs to UCH-L1 or a-synuclein
and so no inhibition of CMA takes place. There are low levels of
misfolded protein which are targeted for degradation via the
ubiquitin-proteasome system and misfolded species remain low so
that aggregates rarely form. The mean values of 100 simulations
are shown in Figure S1.
Overexpressing UCH-L1 + proteasome inhibition (PI)
Time course experiments were carried out to look at UCH-L1
inclusions for up to 8 h post addition of 5 mM MG132 in
transiently transfected cells overexpressing an UCHL1-HA
construct (example of inclusions observed shown in Figure 3A).
Figure 3B shows that inclusions can form as early as 4 h but there
are significantly more by 8 h (p,0.001). We initially modelled
UCH-L1 overexpression by increasing the initial amount of UCH-
L1 and the synthesis rate by a factor of 2 and used an SBML event
structure to decrease the rate of proteasome degradation by 70%
after 20 hours. However, the simulation results showed that there
was much less cell variability in the timing of inclusion formation
than seen in the experimental data. One possible explanation is
that the level of UCH-L1 is not same in each cell. In fact
transfection is not 100% efficient with about 25% of cells
expressing endogenous levels of UCH-L1 in the UCH-L1-
overexpression experiments. Furthermore, some cells may inte-
Figure 1. Typical aggregation kinetics. During the lag phase, the
aggregation process is reversible and aggregate size remains low. Once
a critical size of aggregate is reached, the process is irreversible and the
aggregation process is accelerated (exponential growth phase). The
pool of aggregatable protein is eventually depleted and the curve
reaches a plateau.
doi:10.1371/journal.pone.0013175.g001
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UCH-L1 than the majority of cells in the experiment. Another
possible source of variation is that the expression levels of UCH-L1
may depend on the point of integration of the plasmid into the
host DNA. Therefore, simulations were carried out on three sub-
populations of cells and then the results combined. We assumed
that 25% of simulated cells had endogenous levels of UCH-L1,
50% of simulated cells over-expressed UCH-L1 by a factor of 2,
and 25% of simulated cells overexpressed UCH-L1 by a factor of
3. We only counted inclusions that had an amount greater than
20, since very small inclusions are not detectable by immunoflu-
orescence imaging. The simulation results for a total of 200 runs
are summarized in Table 1 and the percentage of simulated cells
with inclusions has been plotted in Figure 3C with the
experimental data for direct comparison. The figure shows that
the simulated data compares well with the experimental data both
in terms of the mean and the variability. To examine the
importance of stochastic effects we also carried out the same
procedure using a deterministic simulator. The results are shown
in Table 2 and it can be seen that the deterministic solution does
not match the data with too few inclusions occurring at early time
points and too many inclusions at 8 h post PI. This confirms that
Figure 2. Simulation results for normal conditions. This shows how some of the species in the model vary over time in a typical simulation run.
A Generic pool of protein. NatP = Native protein; TotalMisP= unbound misfolded protein + all bound forms of misfolded protein; Total protein =
NatP + TotalMisP. B Ubiquitin pools. Ub conjugates includes all complexes containing ubiquitin not just ubiquitinated proteins (e.g. Ub-UCHL1
complex is included in this pool). C Aggregated protein. SeqAggP= aggregates sequestered into inclusion bodies; AggP=small unbound aggregates
(of all types); AggP_Proteasome=small aggregates bound to the proteasome. D a-synuclein levels: asyn=unbound a-synuclein; asyn_dam=total
pool of damaged a-synuclein (except any that is present in inclusions); total asyn=total pool of a-synuclein. E Pool of unbound proteasomes. F
UCHL1 pools: Free UCHL1=unbound UCHL1; Total UCHL1=total pool of UCHL1 (except any that is present in inclusions); UCHL1 substrate=total
level of the UCHL1 substrate (either bound or unbound).
doi:10.1371/journal.pone.0013175.g002
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production, additional stochastic effects in other cellular processes
are required to explain the experimental data.
The model predictions for a typical simulated cell with high
levels of UCH-L1 (3x baseline) are shown in Figure 4. Note that
where total pools of specific proteins are plotted, these totals do not
include any protein which is present in inclusions. In this
simulation inclusions begin to form at 15 hours, which was
5 hours before proteasome inhibition took place. This is due to
very high levels of UCH-L1 which lead to an increase in the
UCH-L1 substrate and also more damaged UCH-L1. The
increase in damaged UCH-L1 particularly has an effect on the
aggregation process as not only is it possible for UCH-L1 to self-
aggregate but it also binds to Lamp2a receptors and inhibits a-
synuclein degradation. However, during the first few hours, levels
of inclusions (SeqAggP) are very low and probably undetectable.
The model predicts that 27% of cells have inclusions by 24 hours
(4 h post-PI) and this increases to 60.5% by 28 hours (8 h post-PI).
Figure 3. UCH-L1 inclusion formation in COS7 cells over-expressing wild type UCH-L1. Cells were transfected with UCH-L1-HA for a total
of 28 h. 5 mM MG132 was added for the times indicated prior to the end of the experiment. A Typical example of cells overexpressing UCHL1-HA
which contain inclusions. Images immunostained with monoclonal HA (green) and counterstained with DAPI to visualise nuclei (blue). Arrows
indicate the position of inclusions within the cell. B Time course for UCH-L1 inclusion formation. The presence of UCH-L1 was assessed by
immunofluorescence using mouse monoclonal anti-HA antibodies. Bars represent the percentage of cells containing inclusions. Error bars indicate
the standard error from the mean of the experiments. Asterisk indicates a significant difference between the percentage of untreated cells versus the
percentage of treated cells. *p,0.001. no TX = no treatment. C Comparison of experimental data and simulation results for the percentage of cells
containing inclusions in each experiment. Error bars for simulated data represent the standard error for a percentage (s.e =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(p 100{p ðÞ =n
p
, where p
is the percentage and n is the number of simulations).
doi:10.1371/journal.pone.0013175.g003
Table 1. Time course of inclusion formation from stochastic
model simulations.
Number of ‘‘simulated cells’’ with inclusions
UCH-L1 expression
(Number of runs) 4 h post PI 6 h post PI 8 h post PI
3x baseline (50) 37 47 50
2x baseline (100) 16 38 70
baseline (50) 1 1 1
Total (200) 54 86 121
% of simulated cells 27 43 60.5
Experimental data 34 40 54
doi:10.1371/journal.pone.0013175.t001
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protein, E3 ligase and the generic DUB. However there is very
little damage to a-synuclein and no Parkin is contained in the
inclusions generated by this model.
The effects of UCH-L1 overexpression alone can be examined
by studying the graphs before the time at which proteasome
inhibition begins (up to 20 hours). Ubiquitin pools show a very
slight increase from the start of the simulation due to increased
stabilization by UCH-L1. The UCH-L1 substrate increases with
time, since UCH-L1 overexpression leads to increase DUB activity
of its substrate which has the effect of lowering the degradation
rate. When inclusions start to form, the substrate may be
sequestered into the inclusion and so levels of the substrate
increase more slowly and may eventually level off or even start to
decrease. The substrate may be bound by ubiquitin and UCH-L1
when it is sequestered into inclusions.
Overexpression of UCH-L1 does not affect levels of the generic
protein (NatP) before PI. After PI occurs, levels of NatP start to
increase due to less degradation via the proteasome. When inclusions
form, misfolded protein may be sequestered into the inclusion and so
total protein levels increase less steeply. The effect on a-synuclein
varied between simulation runs, although there was usually a slight
increase in levels before PI, in some runs an increase was not seen
until after PI at which point the increase was continued steeply until
inclusions were formed. Since the time at which inclusions starts to
form is very variable, we plotted the aggregation kinetics for six
different simulations runs where UCH-L1 was overexpressed by a
factor of 3 (Figure 5). It can be seen that in some cases (about 10%),
inclusions reach levels of detection before the proteasome is inhibited,
although the rapid increase in inclusion size only occurs after
proteasome inhibition. In simulations where UCH-L1 was overex-
pressed by a factor of two, this happened rarely (,1% of simulated
cells). We also ran the model with UCH-L1 overexpressed three-fold
without proteasome inhibition to check if inclusion formation was
simply due to UCH-L1 overexpression. In this case, the model
predicts that inclusions do start to form between 15 and 22 hours but
growth is much slower and in the majority of cells only reach very low
levels by 28 h (data not shown). This confirms that proteasome
inhibition greatly speeds up the aggregation process.
In order to identify the event or chain of events that leads to
inclusion formation we ran the model using a deterministic simulator
and made a careful comparison of the results with the stochastic
output. We examined the time course of the different species in the
model making a careful distinction of events that occurred before and
after proteasome inhibition. We used the model with UCH-L1
overexpressed by a factor of 2 with proteasome inhibition at 20 hours
for this analysis. Our model output shows that the first event in the
c h a i ni sa ni n c r e a s ei nl e v e l so fd a m a g e dU C H - L 1w h i c hb i n d st o
Lamp2a receptors leading to an increase in a-synuclein levels. The
levels of a-synuclein are now sufficient to form small aggregates and
the deterministic solution shows that on average a cell would have
formed a small inclusion (the seed required for the exponential phase
to begin) before the proteasome is inhibited. After proteasome
inhibition there is a large increase in misfolded protein which then
gets sequestered into the inclusion and so it rapidly grows in size. In
the stochastic model, the seed may not form until after the
proteasome is inhibited and so some cells do not have detectable
inclusions even by 8 h post PI whereas the deterministic model
predicts all cells to have inclusions by 7.2 h post PI.
We assumed that 25% of cells were not transfected and that
25% of cells incorporated more than one extra copy of the
plasmid. It is not easy to measure the exact proportions and so we
examined the effects of varying these proportions in our model.
We found that there was little effect on the model predictions for
the proportions of cells containing inclusions by 8 hours after
proteasome inhibition which was always in the range of 56–62%.
However, lowering the proportion of cells with an extra copy of
the plasmid, led to fewer inclusions at 4 hours post PI with only
10% of cells containing inclusions if in the extreme case we
assumed that no cells incorporated an extra plasmid. An
alternative way to model different expression levels of UCH-L1
would be to use random numbers to decide on the proportions of
cells incorporating one extra plasmid or no plasmid. This would
provide a more stochastic approach to the problem although we
would not expect the model predictions to be greatly affected.
Mutant forms of UCH-L1
I93M mutation. We used the model to examine the possible
effects of UCH-L1 mutations on the aggregation process. To
mimic the effect of the I93M mutation we first assumed that it had
55% lower hydrolase activity than wild-type UCH-L1 [8]. The
simplest way to model this was to adjust the parameter kactUCHL1 to
reflect the relative amount of wild-type and I93M UCH-L1 in the
cell. Our model predicted that there was a small increase in the
number of inclusions at 4 h, 6 h, and 8 h after proteasome
inhibition but the difference was only significant at 6 h (p=0.04).
The reason for the slight increase in inclusion is that more of the
UCH-L1 substrate ends up at the proteasome but is degraded
much less efficiently and is more likely to be sequestered into
inclusions. We then modified the model to allow for the possibility
that the I93M mutant has lower solubility than wild-type UCH-L1
and has similar properties to oxidatively damaged UCH-L1 in
addition to having lower hydrolase activity. We modelled this by
including an additional species UCHL1_mut to represent the
I93M mutant and assumed that this had a higher propensity to
become damaged. If we assumed that the rate of damage was an
order of magnitude higher, then the model predicted that
inclusions containing high levels of a-synuclein and UCH-L1
started to form before proteasome inhibition with 75% of cells
containing inclusions by 4 hours after proteasome inhibition with
only the cells that we had assumed were not transfected without
inclusions. If the rate of damage for mutant UCH-L1 was 50%
higher, then the model predicted that 18% cells contained
inclusions by 4 hours after proteasome inhibition, rising to about
62% by 8 hours post PI. We also ran the model without
proteasome inhibition for 28 hours and in this case, 31% of cells
formed inclusions by the end of the simulations. We also
performed experiments in the laboratory to test the model
predictions and found that the results were in close agreement
Table 2. Time course of inclusion formation from
deterministic model simulations.
Number of ‘‘simulated cells’’ with inclusions
UCH-L1 expression
(Number of runs) 4 h post PI 6 h post PI 8 h post PI
3x baseline (25) 25 25 25
2x baseline (50) 0 0 50
baseline (25) 0 0 0
Total (100) 25 25 75
% of simulated cells 25 25 75
Experimental data 34 40 54
doi:10.1371/journal.pone.0013175.t002
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greater chance of being damaged (Figure 6 and Table S9).
S18Y mutation. It has been suggested that the S18Y mutant has
slightly higher hydrolase activity than wild-type UCH-L1 so we
modelled this mutation by increasing UCH-L1 activity by 20%. The
model predicts that the numberof inclusions is very similar to the
model with wild-type UCH-L1 (Figure 6 and compare Table 1 and
Table S10). Our laboratory experiments show that more inclusions are
observed in untreated cells and those treated with MG132 for 4 hours
with similar levels of inclusions to wild-type for all other time-points
(Figure 6) which indicates that the S18Y mutation is not protective in
our system. This suggests that the S18Y mutant may also behave like
damaged UCH-L1. Therefore, it would be desirable to examine the
binding affinity of S18Y mutant to Lamp2a receptors in order to shed
some light on why more inclusions are observed when SI8Y is over-
expressed. It may be that the beneficial effects of S18Y are only
observed when total levels of UCH-L1 are close to basal levels.
Discussion
We have extended our generic ubiquitin-proteasome model [30]
to include turnover of a-synuclein, UCH-L1, and a substrate of
Figure 4. Overexpression of UCH-L1 (3x baseline) with PI at 20 hours (shown by vertical dashed line). A Generic pool of protein. NatP =
Native protein; TotalMisP= unbound misfolded protein + all bound forms of misfolded protein; Total protein = NatP + TotalMisP. B Ubiquitin pools.
Ub conjugates includes all complexes containing ubiquitin not just ubiquitinated proteins (e.g. Ub-UCHL1 complex is included in this pool). C
Aggregated protein. SeqAggP= aggregates sequestered into inclusion bodies; AggP=small unbound aggregates (of all types); AggP_Protea-
some=small aggregates bound to the proteasome. D a-synuclein levels: asyn=unbound a-synuclein; asyn_dam=total pool of damaged a-synuclein
(except any that is present in inclusions); total asyn=total pool of a-synuclein. E Pool of unbound proteasomes. F UCHL1 pools: Free
UCHL1=unbound UCHL1; Total UCHL1=total pool of UCHL1 (except any that is present in inclusions); UCHL1 substrate=total level of the UCHL1
substrate (either bound or unbound).
doi:10.1371/journal.pone.0013175.g004
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proteins. During the model simulations we can keep track of which
proteins end up in inclusions by using dummy species as products in
the reactions for inclusion formation. We found that the main
components were a-synuclein, ubiquitin, damaged UCH-L1 and
misfolded protein. Due to the high levels of ubiquitin present, we
assume that most of the misfolded protein present was ubiquitinated.
There was also the generic DUB and E3 ligase present in inclusions
indicating that the failure of the proteasome system was responsible
for many of the proteins present in the inclusions. These proteins are
also found in inclusions in laboratory experiments [e.g. 18].
We conducted laboratory experiments to further examine the
effects of UCH-L1 overexpression and proteasome inhibition on
the aggregation process based on our previous work [18]. Our
model showed that the large variability in aggregation kinetics seen
in the experimental system could not be explained by stochastic
effects alone if all cells were identical in respect to the amounts of
proteins that they contained. However, there is intracellular
variability in the expression of UCH-L1 in the experiments and so
we accounted for this in the model by running sets of simulations
with different levels of UCH-L1. In this case, the model
predictions give a close match to the experimental data. We
found that in some simulations, inclusions begin to form even
before proteasome inhibition, when UCH-L1 is overexpressed by
a factor of three. This was due to increased levels of damaged
UCH-L1 and an increase in a-synuclein pools. Therefore we ran
simulations without proteasome inhibition to see if high over-
expression of UCH-L1 alone could lead to inclusions. The model
predicts that although inclusions form by 28 h in the majority of
cells, levels are much lower and we do not see the exponential
Figure 5. A–F Six simulation runs showing variability in aggregation kinetics when UCH-L1 is overexpressed (x3) and proteasome is
inhibited at time t=20 h (shown by vertical dashed line). SeqAggP= aggregates sequestered into inclusion bodies; AggP=small unbound
aggregates (of all types); AggP_Proteasome=small aggregates bound to the proteasome.
doi:10.1371/journal.pone.0013175.g005
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(data not shown). So we conclude that proteasome inhibition
greatly speeds up the aggregation process. This is not surprising
considering the wealth of evidence for the role of proteasome
impairment in neurodegeneration [22,31,32,33,34,35,36,37].
We used the model to examine the effect of UCH-L1 mutations
and then carried out further experiments to test the model
predictions. For the I93M mutation we assumed that either the
mutant had lower hydrolase activity than wild-type or that in
addition the I93M mutant had a greater propensity to be
Figure 6. UCH-L1 inclusion formation in COS7 cells over-expressing mutant forms of UCH-L1. A Cells were transfected with wild type or
mutant UCH-L1 HA tagged plasmids for a total of 28 h. 5 mM MG132 was added for the times indicated prior to the end of the experiment. Time
course for formation. The presence of UCH-L1 was assessed by immunofluorescence using polyclonal UCH-L1 antibodies. Bars represent the
percentage of cells containing inclusions. Error bars indicate the standard error from the mean of the experiments. Asterisk indicates a significant
difference between the percentage of untreated cells versus the percentage of treated cells. **p,0.001. no TX = no treatment. B Percentage of
simulated cells with inclusions for wild-type or mutant UCHL-L1. Error bars indicate standard error for a percentage (s.e =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(p 100{p ðÞ =n
p
, where p is
the percentage and n is the number of simulations).
doi:10.1371/journal.pone.0013175.g006
Modelling Protein Aggregation
PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e13175damaged. We found that the experimental data did not agree with
the model predictions if the only effect of UCH-L1 was reduced
hydrolase activity. We found that the closest agreement between
model predictions and data required that the I93M mutant had a
damage rate that is about 50% higher than wild-type.
We also noted that the results of our short term experiments
revealed differences to our previous longer term ones [31]. The
earlier experiments were carried out for 44 h and we found that
the percentage of cells with inclusions without inhibitors was
similar for wild-type and S18Y mutants, but with MG132 both
S18Y and I93M had higher levels of inclusions than wild-type. It
may be that in longer term transfections the over expressing cells
with S18Y are capable of clearing some of the naturally occurring
inclusions. Conversely, elevated levels of inclusions observed with
I93M without inhibitor in our earlier work may be caused due to
increased sensitivity of the cells to over expression of mutant
protein. This suggests that prolonged expression of mutant protein
is required in order to see effects. This is not dissimilar to what
seen in disease, as familial patients survive several decades before
symptoms present [11].
Mitochondrial dysfunction has been linked to neurodegenera-
tive diseases and the evidence is especially strong in Parkinson’s
disease. Parkin plays a key role in mitochondrial dynamics and is
linked to the PTEN-induced putative kinase 1 protein, PINK1
(Q9BXM7) (reviewed in [38]). There is also recent evidence to
suggest that Parkin and PINK1 act together to maintain
mitochondrial homeostasis by targeting dysfunctional mitochon-
dria for mitophagy [39]. We are currently developing a model of
mitochondrial dynamics as it is our intention to eventually develop
an integrative model of the network involved in preventing protein
aggregation.
It is known that proteasome efficiency declines with age and that
this can result in an accumulation of damaged and misfolded
proteins [40]. There is also a decline in lysosomal degradation due
to an increase in lipofuscin and dysfunctional mitochondria
[41,42,43]. In addition, there is evidence that there is crosstalk
between proteasomal and lysosomal pathways and inhibition of
one pathway ultimately leads to inhibition of the other probably
due to an overload of the systems [44,45]. This will lead to an
increase in protein aggregates which themselves inhibit the
proteasome and may also increase levels of reactive oxygen
species so that a vicious cycle might ensue. The decrease in protein
degradation will also lead to an increase in the pools of proteins
especially those with short half-lives unless protein synthesis is also
downregulated. In tissues which express UCH-L1, a gradual
increase in levels of this protein with age may be particularly
problematic since it is particularly susceptible to oxidative damage
and subsequently inhibits chaperone-mediated autophagy. Figure 7
illustrates the effects of a disturbance in protein homeostasis: (A)
under normal conditions, damaged proteins are cleared by
proteasomes or lysosomes and there is no protein aggregation;
(B) when proteasomes and/or lysosomes become inhibited, UCH-
L1 levels rise and the pool of damaged UCH-L1 also increases.
This leads to inhibition of chaperone-mediated autophagy and
also less degradation of UCH-L1 substrates via the ubiquitin-
proteasome system. As a result protein aggregates start to form
leading to further proteasome inhibition and increased levels of
oxidative stress. The initiating event in this vicious cycle could be
one of several candidates. For example, it could be an increase in
oxidative stress which leads to an increase in damaged protein; an
increase in UCH-L1 pools due to decreased degradation; or
inhibition of lysosomal pathways due to lipofuscin or dysfunctional
Figure 7. The involvement of UCH-L1 in exacerbating any disturbances in protein homeostasis: A under normal conditions,
damaged proteins are cleared by proteasomes or lysosomes and there is no protein aggregation; B when proteasomes and/or
lysosomes become inhibited, UCH-L1 levels rise and the pool of damaged UCH-L1 also increases. This leads to inhibition of chaperone-
mediated autophagy and also less degradation of UCH-L1 substrates via the ubiquitin-proteasome system. As a result protein aggregates start to
form leading to further proteasome inhibition and increased levels of oxidative stress. The grey scale indicates the abundance of each species with
white representing very low levels and dark grey representing high levels. Degradation is represented by the empty set symbol (1).
doi:10.1371/journal.pone.0013175.g007
Modelling Protein Aggregation
PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13175mitochondria. It is likely that stochastic factors will also play an
important role since the actual components damaged will have a
large effect on subsequent outcomes. The timing of events will also
be highly dependent on stochastic effects and could explain why
there is large variability in the age of onset of disease. Our
experimental system and model can be used to examine the
changes that occur during ageing and age-related disease by
accelerating the processes involved.
Materials and Methods
Building the model
We extended our earlier model of the ubiquitin-proteasome
system [30] to include detail of UCH-L1 and a-synuclein. The
original model was encoded in the SBML [29] so that it was
straight-forward to modify and extend. There are many freely
available tools for building and modify SBML models (www.sbml.
org). We used SBML shorthand and a Python script to convert the
code into full SBML [46]. Since there is large variability in
biological data, we have built stochastic models, and simulations
are run using the Gillespie algorithm [47] on the BASIS (Biology
of Ageing e-Science Integration and Simulation) system [48,49].
The model is freely available from the BASIS website (www.basis.
ncl.ac.uk) and the Biomodels database [50,51] (ID:MO-
DEL0912070000). The SBML code is also available in the
supporting information (Dataset S1).
The model is quite large but can be split up into eight
components: a generic model of the ubiquitin-proteasome system;
UCH-L1 turnover, UCH-L1 stabilisation of ubiquitin pools;
UCH-L1 hydrolase activity, UCH-L1 damage; a-synuclein
turnover, a-synuclein damage; and protein aggregation. Each
component is described in turn and each individual component is
itself a complete model which can be tested. The components are
then linked together to form an integrative model. Full details of
the model species and reactions are given in the supporting
information in Tables S1, S2, S3 and S4. Further details of the
parameter values are also described in the supporting information
(Supporting Text S1).
Generic model of the ubiquitin-proteasome system
This component is based on the already published model of the
ubiquitin-proteasome system [30]. The original model assumed
that total ubiquitin pools are constant. However, ubiquitin is
upregulated after stress and ubiquitin itself is turned over by
proteasomes and so the model has been slightly modified to
include ubiquitin turnover. This required the addition of three
reactions: basal synthesis, degradation and stress-induced synthesis
of ubiquitin (Table S5). We assume that the rate of stress-induced
synthesis depends on the level of misfolded protein in the cell.
UCH-L1 turnover
We assume that UCH-L1 can be degraded by lysosomes and
proteasomes. This component consists of just four reactions:
synthesis, binding to the proteasome, degradation by the
proteasome and degradation by lysosomes (Table S6).
Regulation of monomeric ubiquitin pools
UCH-L1 binds to ubiquitin (by monoubiquitination) and
prevents ubiquitin (Ub) degradation. This is reversible, so when
pools of Ub are low, Ub is released from UCH-L1. This enables
Ub levels to increase rapidly before upregulation takes place which
is subject to a delay due to the time required for protein synthesis.
When Ub pools are sufficient again, Ub can bind to UCH-L1. We
assume that the affinity of UCH-L1 to Ub is less than affinity of
Ub to E1 and E2 enzymes, so that it only binds surplus pools
(Table S6).
Hydrolase activity
The substrates of UCH-L1 are currently unknown so we
include a pool of a generic substrate named SUB. We assume that
UCH-L1 first binds (reversibly) to the ubiquitinated (or poly-
ubiquitinated) substrate and removes Ub processively (Table S6).
Damage of UCH-L1
We assume that UCH-L1 may be oxidatively damaged by
reactive oxygen species (ROS (CHEBI:26523)) which causes it to
lose its activity. We assume that damaged UCH-L1 will bind to the
Lamp2a receptor which prevents binding of CMA substrates to
the receptor (Table S6).
a-synuclein turnover
We assume that a-synuclein is degraded by the proteasome
without the need for ubiquitination (only mutated forms require
ubiquitination), or chaperone-mediated autophagy which requires
binding of a-synuclein to the Lamp2a receptor (Table S7).
a-synuclein damage
We assume that a-synuclein may be damaged by ROS and it is
then ubiquitinated by Parkin and degraded via the 26S
proteasome (Table S7).
Aggregation of protein
We assume that any misfolded protein can interact with another
misfolded protein to form a small aggregate. An aggregate can
grow in size by the addition of further misfolded proteins and may
decrease in size by the removal of misfolded proteins with the aid
of the chaperone machinery. However, when the aggregate
reaches a certain threshold size, disaggregation can no longer take
place and instead an inclusion forms. This threshold represents the
seed and is assumed to be of size six based on data for amyloid
fibril polymerization [52]. For simplicity we assume that misfolded
species only interact with other species that are of the same type,
i.e. a-synuclein may interact with itself but not with a generic
misfolded protein. The model contains 5 different species which
may aggregate: generic misfolded protein; a substrate of UCH-L1
in its misfolded state; native a-synuclein; damaged a-synuclein;
and damaged UCH-L1. We assume that damaged protein has a
greater propensity to aggregate than native protein. Once an
inclusion forms, any misfolded or damaged protein may be
sequestered even if it is ubiquitinated or bound to E3 ligases
although the rate of this happening is normally very low. This
must occur since E3 ligases, chaperones and ubiquitin are found in
inclusion bodies [18]. The circumstances in which this would
occur is when the ubiquitin proteasome system is overwhelmed
and degradation slows down so that these misfolded proteins
persist for longer time periods and therefore are more likely to be
sequestered into inclusions. The larger the amount of inclusions in
the cell, the more likely they are to increase in size and so inclusion
growth may be very rapid after cellular stress. We assume that
inclusions are a protective mechanism and that they do not
interfere with the cellular machinery. On the other hand, we
assume that small aggregates are detrimental since they may bind
to the proteasome and inhibit proteasomal activity and that they
may also cause an increase in ROS production. The reactions for
aggregation are listed in the supporting information (Tables S5, S6
and S7).
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affected the kinetics of aggregate formation. The results are
reported in Table S8 and discussed in the supporting information
(Supporting Text S1).
Experimental procedures
Early time course experiments to look at UCH-L1
inclusions. COS7 cells were transfected with 2 mg UCHL1-
HA, S18Y-HA or I93M-HA plasmid DNA in 2% FCS containing
media as previously described [18]. Cells were untreated, treated
with the carrier DMSO or treated with 5 mM MG132 for 4, 6 or
8 h and the experiment was terminated at 28 h post transfection.
Cells were processed for immunofluorescence using monoclonal
262K HA antibody (Cell Signalling Technologies) or polyclonal
anti-UCHL1 (PGP 9.5, Biomol) as previously described [18]. A
Nikon Eclipse TE-2000-E microscope was used to observe the
number of cells containing inclusions A minimum of 300
transfected cells were counted from blinded samples. This was
repeated at least 2 or 3 times. It was not possible to count the
actual number of inclusions per cell and so cells were scored either
as containing inclusions or having no inclusions. Then the
percentage of cells with inclusions was calculated for each
experiment. Data was processed by one way Anova (Bonferroni)
statistical analysis using SSPS 16.0 for Windows. Images were
captured using Velocity 5 (Improvision) software.
Supporting Information
Text S1 Further details of the model and simulation methods.
Found at: doi:10.1371/journal.pone.0013175.s001 (0.06 MB
DOC)
Figure S1 Plot of mean values for 100 runs of model under
normal conditions. A Generic pool of protein. NatP = Native
protein; TotalMisP= unbound misfolded protein + all bound
forms of misfolded protein; Total protein = NatP + TotalMisP. B
Ubiquitin pools. Ub conjugates includes all complexes containing
ubiquitin not just ubiquitinated proteins (e.g. Ub-UCHL1 complex
is included in this pool). C Aggregated protein. SeqAggP=
aggregates sequestered into inclusion bodies; AggP=small un-
bound aggregates (of all types); AggP_Proteasome=small aggre-
gates bound to the proteasome. D a-synuclein levels: asyn=un-
bound a-synuclein; asyn_dam=total pool of damaged a-synuclein
(except any that is present in inclusions); total asyn=total pool of
a-synuclein. E Pool of unbound proteasomes. F UCHL1 pools:
Free UCHL1=unbound UCHL1; Total UCHL1=total pool of
UCHL1 (except any that is present in inclusions); UCHL1
substrate=total level of the UCHL1 substrate (either bound or
unbound)
Found at: doi:10.1371/journal.pone.0013175.s002 (0.17 MB TIF)
Table S1 Model species for generic UPS component.
Found at: doi:10.1371/journal.pone.0013175.s003 (0.05 MB
DOC)
Table S2 Model species for UCHL1 turnover, activity, damage
and aggregation.
Found at: doi:10.1371/journal.pone.0013175.s004 (0.04 MB
DOC)
Table S3 Model species for a-synuclein turnover, damage and
aggregation.
Found at: doi:10.1371/journal.pone.0013175.s005 (0.04 MB
DOC)
Table S4 Dummy species used to identify different proteins in
inclusions.
Found at: doi:10.1371/journal.pone.0013175.s006 (0.03 MB
DOC)
Table S5 Reactions for generic UPS component.
Found at: doi:10.1371/journal.pone.0013175.s007 (0.07 MB
DOC)
Table S6 Reactions for UCH-L1 turnover, activity, damage and
aggregation.
Found at: doi:10.1371/journal.pone.0013175.s008 (0.06 MB
DOC)
Table S7 Reactions for a-synuclein turnover, damage and
aggregation.
Found at: doi:10.1371/journal.pone.0013175.s009 (0.06 MB
DOC)
Table S8 List of parameters which have an effect on inclusion
formation.
Found at: doi:10.1371/journal.pone.0013175.s010 (0.03 MB
DOC)
Table S9 Results for I93M mutant. Mutant has lower hydrolase
activity and has 50% higher damage rate than wild-type.
Found at: doi:10.1371/journal.pone.0013175.s011 (0.03 MB
DOC)
Table S10 Results for S18Y mutant. Mutant has higher
hydrolase activity.
Found at: doi:10.1371/journal.pone.0013175.s012 (0.03 MB
DOC)
Dataset S1 SBML code of model for normal conditions.
Found at: doi:10.1371/journal.pone.0013175.s013 (0.01 MB
TAR)
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